Software has supported healthcare administration for decades through scheduling systems and billing platforms. It is a different idea entirely for software itself to function as the treatment. That is the premise behind digital therapeutics, a category built specifically around evidence-based clinical intervention delivered through an app or digital platform.
What Makes a Product a Digital Therapeutic?
A digital therapeutic is defined by clinical intent, evidence, and outcome measurement, not simply by being a health-related app. It must deliver a therapeutic intervention directly to patients, driven by software, and typically requires clinical evidence demonstrating measurable health impact. Patient engagement design and structured outcome measurement distinguish true digital therapeutics from general wellness apps that share loose similarities on the surface.
DTx vs Digital Health vs Wellness Apps
| Category | Clinical Evidence Requirement | Regulatory Oversight | Example Purpose |
|---|---|---|---|
| Digital therapeutics | Required, often clinical trials | Often regulated as medical devices | Treating a specific condition |
| Digital health tools | Variable | Limited | Supporting general care coordination |
| Wellness apps | Typically none required | None | General health tracking or motivation |
This distinction matters practically. A meditation app promoting general stress reduction is a wellness tool. A software program clinically validated to treat diagnosed insomnia through structured cognitive behavioral therapy protocols is a digital therapeutic.
How a Digital Therapeutic Fits Into Care
A patient is typically identified as a candidate for a specific digital therapeutic based on a diagnosed condition, sometimes through a formal prescription or clinical recommendation depending on the product’s regulatory classification. The patient then uses the software as directed, often following a structured program over a defined period.
Data collected during use feeds back to the clinical team, supporting monitoring and adjustment much like a traditional treatment plan would. Outcome evaluation, whether through symptom scales, biomarkers, or other measures, determines whether the intervention is working as intended.
The Main Clinical Areas for DTx
Mental health has produced some of the most established digital therapeutics, particularly for depression, anxiety, and insomnia, where structured cognitive behavioral therapy protocols translate reasonably well into software-delivered formats. Substance use disorder treatment represents another area with regulatory-cleared digital therapeutic products supporting recovery programs.
Chronic disease management, including diabetes and hypertension, has seen digital therapeutics focused on behavior change and self-management support. Neurology applications target conditions including ADHD, with at least one digital therapeutic receiving regulatory clearance specifically for pediatric attention difficulties. Sleep and broader behavioral medicine round out the categories where digital therapeutics have gained the most traction.
How Digital Therapeutics Are Evaluated
Clinical trials remain the gold standard for digital therapeutic evidence, similar to pharmaceutical evaluation, though trial design for software interventions differs in important ways from drug trials. Safety evaluation focuses less on physiological side effects and more on data privacy, appropriate use boundaries, and ensuring the software does not cause harm through misuse or over-reliance.
| Evaluation Factor | What It Measures |
|---|---|
| Efficacy | Whether the intervention produces the intended clinical effect |
| Safety | Data privacy, appropriate use, absence of harm |
| Usability | Whether patients can use the product as intended |
| Adherence | Whether patients actually engage with the program consistently |
| Real-world performance | Whether trial results hold up outside controlled settings |
Adherence deserves particular attention in this category, since a digital therapeutic that patients stop using after a week provides no clinical benefit regardless of how strong its trial data looked under supervised conditions.
The Business Models Behind DTx
Prescription digital therapeutics require a clinician’s prescription before patient access, mirroring pharmaceutical distribution and often supporting reimbursement conversations with payers. Provider-integrated models embed digital therapeutics directly into existing care pathways, often bundled with broader treatment programs rather than sold as standalone products.
Payer-supported models involve insurance companies covering digital therapeutic costs, typically requiring strong outcome evidence to justify coverage decisions. Direct-to-consumer models exist as well, though products without a therapeutic-grade evidence base marketed this way blur the line back toward general wellness apps.
What Has Gone Wrong in the DTx Market?
Patient engagement has proven far more difficult than many digital therapeutic companies initially anticipated, with real-world usage often falling well short of clinical trial adherence rates. Reimbursement uncertainty has also slowed growth, since many payers remain cautious about covering a treatment category still building a long-term evidence track record.
Regulatory uncertainty in some jurisdictions has created additional friction for companies trying to bring new products to market. Several notable digital therapeutics companies have faced business sustainability challenges in recent years, illustrating that clinical evidence alone does not guarantee a viable business model without solving reimbursement and engagement simultaneously.
Where DTx Could Go Next
AI personalization is an increasingly common direction, with digital therapeutics adapting content and pacing based on individual patient response patterns rather than delivering a fixed program to everyone. Integration with biomarkers and connected devices could allow digital therapeutics to adjust based on physiological data rather than self-reported symptoms alone.
Combination therapy models, pairing digital therapeutics with traditional medication or in-person care rather than positioning them as standalone alternatives, appear increasingly likely to define the category’s next phase, particularly as clinical evidence continues to mature.
How Clinicians Decide Whether to Recommend a Digital Therapeutic
Providers considering a digital therapeutic for a patient typically weigh several factors beyond the underlying clinical evidence alone. Patient comfort with technology plays a meaningful role, since a program requiring daily app engagement may suit a tech-savvy younger patient far better than an older patient less comfortable navigating a smartphone interface. Condition severity also factors into this decision, with digital therapeutics generally better suited to mild-to-moderate presentations than severe or complex cases requiring more intensive, closely supervised treatment.
Cost and access considerations remain practically significant as well. A digital therapeutic requiring out-of-pocket payment without insurance coverage may simply be unaffordable for many patients, regardless of how strong its clinical evidence looks on paper. Providers increasingly weigh these practical access questions alongside pure clinical appropriateness when deciding whether a digital therapeutic represents a genuinely viable option for a specific patient’s circumstances.
FAQ
Q: What are digital therapeutics?
A: Digital therapeutics are software-based interventions designed to treat, manage, or prevent a specific medical condition, supported by clinical evidence and often subject to regulatory oversight.
Q: How are digital therapeutics different from health apps?
A: Digital therapeutics require clinical evidence of therapeutic effect and often regulatory clearance, while general health apps typically lack these requirements and focus on wellness rather than treatment.
Q: Are digital therapeutics FDA regulated?
A: Some digital therapeutics are regulated as medical devices and require clearance before marketing, though regulatory pathways vary depending on the product’s specific claims and risk level.
Q: What conditions can DTx treat?
A: Common applications include depression, anxiety, insomnia, substance use disorder, ADHD, and chronic disease management support such as diabetes and hypertension.
Q: Are digital therapeutics prescribed?
A: Some digital therapeutics require a clinician’s prescription, similar to medication, while others are available directly to consumers depending on their regulatory classification.
Q: Do digital therapeutics work?
A: Evidence varies by product. Digital therapeutics with strong clinical trial support have shown meaningful outcomes for certain conditions, though real-world adherence often falls short of trial conditions.
Q: What are the challenges facing DTx?
A: Patient engagement and adherence, reimbursement uncertainty, and business sustainability remain significant challenges across the digital therapeutics industry.